Eli Lilly and Company (LLY.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
As of 01:14PM CEST. Market open.
| Previous close | 686.20 |
| Open | 677.20 |
| Bid | 675.70 x 0 |
| Ask | 676.60 x 0 |
| Day's range | 673.20 - 678.30 |
| 52-week range | 342.40 - 737.50 |
| Volume | |
| Avg. volume | 6,598 |
| Market cap | 642.623B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 124.70 |
| EPS (TTM) | 5.42 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 4.75 (0.69%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
ZacksWill Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
ZacksAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.